The skytrofa market research report is one of a series of new reports that provides skytrofa market statistics, including skytrofa industry global market size, regional shares, competitors with a skytrofa market share, detailed skytrofa market segments, market trends and opportunities, and any further data you may need to thrive in the skytrofa industry. This skytrofa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to growing government initiatives, increased elderly population, increasing prevalence of growth hormone deficiency, rising chronic disease prevalence, and rising number of clinical trials. Major trends in the forecast period include technological innovations, technological advancements in drug delivery systems, artificial intelligence (AI), technological innovations in drug delivery, and a shift toward pediatric treatment innovation.
The growing demand for hormone replacement therapy is expected to drive the expansion of the Skytrofa market in the future. Hormone replacement therapy (HRT) is used to replace hormones, such as estrogen and progesterone, to manage symptoms associated with menopause or hormonal imbalances. The increasing demand for HRT is largely due to an aging population and the increasing awareness of its effectiveness in alleviating menopause-related symptoms. Skytrofa is used in hormone replacement therapy to treat growth hormone deficiency by stimulating growth and development through subcutaneous injections. For example, in October 2023, the National Health Service in the UK reported that 11 million HRT prescriptions were issued during 2022-2023, reflecting a 47% increase from the previous year. Additionally, about 2.3 million patients received HRT prescriptions, marking a 29% rise compared to the previous year. This growing demand for HRT is expected to contribute to the market growth of Skytrofa.
The increase in healthcare expenditure is expected to drive the growth of the Skytrofa market as well. Healthcare expenditure refers to the total spending on medical services, treatments, and healthcare-related costs. The rise in healthcare spending is driven by the aging population and the increasing prevalence of chronic diseases, both of which require more frequent medical interventions and long-term care. Higher healthcare spending supports Skytrofa by funding research, improving treatment accessibility, and ensuring that patients with growth hormone deficiency have insurance coverage. According to The Health Foundation, in November 2024, planned day-to-day Department of Health and Social Care (DHSC) spending increased from $222.2 billion (£177.9 billion) in 2023-24 to $234.7 billion (£190.1 billion) in 2024-25, and it is projected to rise further to $249.4 billion (£200.5 billion) by 2025-26, reflecting an average annual growth rate of 3.3%. This increase in healthcare expenditure is likely to drive further growth in the Skytrofa market.
A notable trend in the Skytrofa market is the development of long-acting growth hormone formulations aimed at improving patient convenience and treatment adherence. Long-acting growth hormones are designed to be administered less frequently, such as on a weekly or monthly basis, while still maintaining their therapeutic effects, as opposed to daily injections. For instance, in September 2023, Ascendis Pharma A/S, a Denmark-based biotechnology company, launched SKYTROFA (lonapegsomatropin) in Germany. This once-weekly treatment is aimed at children and adolescents aged 3 to 18 years with growth hormone deficiency. By utilizing pegylation technology to extend the medication's half-life, this treatment only requires a single injection per week, offering a more convenient dosing schedule compared to daily therapies. This innovation is intended to enhance patient adherence, reduce the burden of frequent injections, and ultimately improve the overall quality of care for young patients.
The countries covered in the skytrofa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Skytrofa is a long-acting recombinant human growth hormone (rhGH) used to treat pediatric growth hormone deficiency (GHD) through weekly subcutaneous injections. It stimulates growth in children with GHD and offers a more convenient alternative to daily growth hormone treatments.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Skytrofa include growth hormone deficiency (GHD), idiopathic short stature (ISS), and Prader-Willi syndrome (PWS). GHD occurs when the pituitary gland does not produce enough growth hormone, a crucial substance for growth, cell reproduction, and regeneration. Skytrofa is available in liquid formulations for subcutaneous injection and is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end users, such as hospitals, clinics, ambulatory care centers, and home care settings.
The skytrofa market consists of sales of skytrofa injection devices, skytrofa diagnostic kits and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing government initiatives, increased elderly population, increasing prevalence of growth hormone deficiency, rising chronic disease prevalence, and rising number of clinical trials. Major trends in the forecast period include technological innovations, technological advancements in drug delivery systems, artificial intelligence (AI), technological innovations in drug delivery, and a shift toward pediatric treatment innovation.
The growing demand for hormone replacement therapy is expected to drive the expansion of the Skytrofa market in the future. Hormone replacement therapy (HRT) is used to replace hormones, such as estrogen and progesterone, to manage symptoms associated with menopause or hormonal imbalances. The increasing demand for HRT is largely due to an aging population and the increasing awareness of its effectiveness in alleviating menopause-related symptoms. Skytrofa is used in hormone replacement therapy to treat growth hormone deficiency by stimulating growth and development through subcutaneous injections. For example, in October 2023, the National Health Service in the UK reported that 11 million HRT prescriptions were issued during 2022-2023, reflecting a 47% increase from the previous year. Additionally, about 2.3 million patients received HRT prescriptions, marking a 29% rise compared to the previous year. This growing demand for HRT is expected to contribute to the market growth of Skytrofa.
The increase in healthcare expenditure is expected to drive the growth of the Skytrofa market as well. Healthcare expenditure refers to the total spending on medical services, treatments, and healthcare-related costs. The rise in healthcare spending is driven by the aging population and the increasing prevalence of chronic diseases, both of which require more frequent medical interventions and long-term care. Higher healthcare spending supports Skytrofa by funding research, improving treatment accessibility, and ensuring that patients with growth hormone deficiency have insurance coverage. According to The Health Foundation, in November 2024, planned day-to-day Department of Health and Social Care (DHSC) spending increased from $222.2 billion (£177.9 billion) in 2023-24 to $234.7 billion (£190.1 billion) in 2024-25, and it is projected to rise further to $249.4 billion (£200.5 billion) by 2025-26, reflecting an average annual growth rate of 3.3%. This increase in healthcare expenditure is likely to drive further growth in the Skytrofa market.
A notable trend in the Skytrofa market is the development of long-acting growth hormone formulations aimed at improving patient convenience and treatment adherence. Long-acting growth hormones are designed to be administered less frequently, such as on a weekly or monthly basis, while still maintaining their therapeutic effects, as opposed to daily injections. For instance, in September 2023, Ascendis Pharma A/S, a Denmark-based biotechnology company, launched SKYTROFA (lonapegsomatropin) in Germany. This once-weekly treatment is aimed at children and adolescents aged 3 to 18 years with growth hormone deficiency. By utilizing pegylation technology to extend the medication's half-life, this treatment only requires a single injection per week, offering a more convenient dosing schedule compared to daily therapies. This innovation is intended to enhance patient adherence, reduce the burden of frequent injections, and ultimately improve the overall quality of care for young patients.
The key company operating in the skytrofa market is Ascendis Pharma A/S
North America was the largest region in the skytrofa market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in skytrofa report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the skytrofa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Skytrofa is a long-acting recombinant human growth hormone (rhGH) used to treat pediatric growth hormone deficiency (GHD) through weekly subcutaneous injections. It stimulates growth in children with GHD and offers a more convenient alternative to daily growth hormone treatments.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Skytrofa include growth hormone deficiency (GHD), idiopathic short stature (ISS), and Prader-Willi syndrome (PWS). GHD occurs when the pituitary gland does not produce enough growth hormone, a crucial substance for growth, cell reproduction, and regeneration. Skytrofa is available in liquid formulations for subcutaneous injection and is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end users, such as hospitals, clinics, ambulatory care centers, and home care settings.
The skytrofa market consists of sales of skytrofa injection devices, skytrofa diagnostic kits and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Skytrofa Market Characteristics4. Skytrofa Market Trends And Strategies5. Skytrofa Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Skytrofa Pricing Analysis & Forecasts30. Global Skytrofa Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Skytrofa Market32. Recent Developments In The Skytrofa Market
3. Skytrofa Market Biologic Drug Characteristics
6. Global Skytrofa Growth Analysis And Strategic Analysis Framework
8. Skytrofa Market Segmentation
9. Global Skytrofa Epidemiology Of Clinical Indications
10. Skytrofa Market Regional And Country Analysis
11. Asia-Pacific Skytrofa Market
12. China Skytrofa Market
13. India Skytrofa Market
14. Japan Skytrofa Market
15. Australia Skytrofa Market
16. South Korea Skytrofa Market
17. Western Europe Skytrofa Market
18. UK Skytrofa Market
19. Germany Skytrofa Market
20. France Skytrofa Market
21. Eastern Europe Skytrofa Market
22. North America Skytrofa Market
23. USA Skytrofa Market
24. Canada Skytrofa Market
25. South America Skytrofa Market
26. Middle East Skytrofa Market
27. Africa Skytrofa Market
28. Skytrofa Market Competitive Landscape And Company Profiles
29. Global Skytrofa Market Pipeline Analysis
33. Skytrofa Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Skytrofa Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on skytrofa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for skytrofa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The skytrofa market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Growth Hormone Deficiency (GHD); Turner Syndrome; Idiopathic Short Stature (ISS); Prader-Willi Syndrome (PWS)2) By Formulation: Liquid Formulation; Subcutaneous Injection
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Hospital; Clinicals; Ambulatory Care; Home Care
Key Companies Profiled: Ascendis Pharma A/S
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Ascendis Pharma A/S
